8-K: Klotho Neurosciences Secures $2 Million Investment via Convertible Notes and Warrants

Klotho Neurosciences enters into a securities purchase agreement for a $2 million investment involving convertible notes and warrants with an institutional investor.

Summary

• Klotho Neurosciences, Inc. has entered into a Securities Purchase Agreement with an institutional investor for a $2 million investment.
• The agreement involves the issuance of senior convertible promissory notes with an aggregate principal amount of $2,173,914 and warrants to purchase up to 4,000,000 shares of common stock.
• The first closing occurred on January 23, 2025, for $1 million, involving a note of $1,086,957 and a warrant for 2,000,000 shares.
• The notes bear interest at 7% per annum and have an 8% original issuance discount.
• The notes are convertible into common stock at $0.25 per share, subject to certain ownership limitations and Nasdaq rules.
• The warrants are exercisable at $0.50 per share and expire five years from issuance, also subject to ownership limitations.
• The company is required to seek stockholder approval within 90 days for the issuance of shares exceeding 19.99% of outstanding common stock.
• A registration rights agreement mandates the company to file a registration statement with the SEC within 15 days to register the shares issuable upon conversion or exercise.
• A voting agreement is in place with officers, directors, and major stockholders to vote in favor of the issuance of more than 20% of the outstanding shares of common stock to the investor.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The company secures funding, but faces potential dilution and restrictions.

Positives

• The investment provides Klotho Neurosciences with $2 million in funding for general corporate purposes.
• The registration rights agreement ensures liquidity for the investor by allowing for the potential resale of shares.
• The voting agreement increases the likelihood of stockholder approval for the issuance of shares, facilitating the conversion of notes and exercise of warrants.

Negatives

• The conversion of notes and exercise of warrants may result in dilution of existing shareholders' equity.
• The company is subject to certain restrictions and covenants, including limitations on incurring additional debt and issuing certain types of securities.
• Failure to obtain stockholder approval could trigger cash payment obligations to the investor.

Risks

• The company's ability to meet its obligations under the agreement depends on various factors, including market conditions and regulatory approvals.
• The investor's ownership is capped at 4.99% (or 9.99% with notice) of the outstanding common stock, which may limit their potential gains.
• The company faces potential penalties for failing to deliver shares on time or to maintain an effective registration statement.

Future Outlook

The company intends to use the proceeds from the sale of the notes for general corporate purposes and is obligated to seek stockholder approval for the issuance of shares exceeding 19.99% of the outstanding common stock.

Industry Context

This announcement reflects a common financing strategy for small-cap companies, utilizing convertible notes and warrants to attract investment. The specific terms, such as the conversion price and warrant exercise price, are indicative of the company's current valuation and growth potential.

Comparison to Industry Standards

• Comparable companies in the biotechnology or pharmaceutical sectors often utilize similar financing structures, such as convertible notes and warrants, to raise capital.
• The terms of the agreement, including the interest rate, conversion price, and warrant exercise price, are generally within the range of industry standards for similar transactions.
• The requirement for stockholder approval for share issuances exceeding a certain threshold is a common provision to protect existing shareholders from excessive dilution.

Stakeholder Impact

• Shareholders may experience dilution if the notes are converted and warrants are exercised.
• The company's employees and customers may benefit from the additional funding, which could support research and development efforts.
• The company's creditors may be affected by the issuance of senior convertible notes, which could impact the company's ability to repay its debts.

Next Steps

• The company must file a registration statement with the SEC within 15 days.
• The company must seek stockholder approval within 90 days for the issuance of shares exceeding 19.99% of outstanding common stock.
• The investor may exercise its conversion and warrant rights in the future.

Key Dates